LuciOlap — Olaparib 150 mg, 120 pcs, Lucius

LuciOlap — Olaparib Tablets 150 mg, 120 Tablets

Product code: 509

25032₴ 27267₴ -8% On order · from 10 days

Analogues

1
Active ingredient
Dosage
150 mg
Dosage form Tablets
Tablets per pack 120

LuciOlap is an advanced targeted antineoplastic agent belonging to the poly (ADP-ribose) polymerase (PARP) inhibitor class, indicated for the treatment of hereditary or sporadic forms of ovarian, breast, pancreatic, and prostate cancers. The active pharmaceutical ingredient is olaparib at a strength of 150 mg supplied as film-coated tablets (Olaparib Film-coated Tablets 150 mg). The product is developed and manufactured by Lucius Pharmaceuticals.

Olaparib is a potent inhibitor of PARP enzymes (PARP1, PARP2, and PARP3). PARP enzymes play a critical role in DNA single-strand break repair. Inhibiting PARP in cells with homologous recombination deficiency (such as BRCA1 or BRCA2 mutations) leads to the accumulation of unrepaired DNA double-strand breaks, resulting in tumor cell death via the "synthetic lethality" mechanism. The drug is highly effective as maintenance and monotherapy.

Supplied in a package containing 120 tablets of 150 mg. Intended exclusively for oral administration under the strict supervision of an oncologist.

Key Clinical Features and Advantages of LuciOlap 150 mg:

  • ✅ First-in-Class PARP Inhibitor: Selective blockade of DNA repair in BRCA-deficient tumors.
  • ✅ Synthetic Lethality Principle: Selective destruction of cancer cells while sparing most healthy tissues.
  • ✅ Broad Indications: Proven efficacy in ovarian, breast, pancreatic, and prostate cancers.
  • ✅ Convenient Oral Dosing: Taken orally twice daily regardless of food intake.
  • ✅ Lucius Pharmaceuticals Standards: High-quality, accessible generic alternative to the originator product (Lynparza).

LuciOlap is supplied as film-coated tablets for oral administration.

Qualitative and Quantitative Composition per Tablet:

  • Active Ingredient: Olaparib — 150 mg.
  • Excipients: Copovidone, colloidal anhydrous silica, mannitol, sodium stearyl fumarate. Coating: hypromellose, titanium dioxide, macrogol, iron oxide yellow.

Packaging and Presentation: Film-coated tablets, 150 mg strength. Each package contains 120 tablets along with prescribing information. Labeled with LuciOlap (Olaparib Film-coated Tablets 150 mg) and Lucius Pharmaceuticals corporate graphics.

Pharmacodynamics:
Olaparib is an inhibitor of poly (ADP-ribose) polymerase (PARP1, PARP2, PARP3) enzymes. PARP enzymes are required for the repair of DNA single-strand breaks. Inhibition of PARP by olaparib results in the trapping of PARP proteins on damaged DNA, formation of double-strand breaks, and cell death. In cells with defective BRCA1/2 genes or other homologous recombination components, the repair of such breaks is impossible, leading to selective tumor cell death (synthetic lethality).

Pharmacokinetics:

  • Absorption: Following oral administration, olaparib is absorbed relatively rapidly; peak plasma concentration (Tmax) is achieved within approximately 1.5 to 3 hours. Food intake slightly delays absorption but imposes no strict limitations.
  • Distribution: Human plasma protein binding is approximately 82%.
  • Metabolism: Extensively metabolized in the liver, primarily via CYP3A4 enzyme of the cytochrome P450 system.
  • Elimination: Excreted predominantly renally (approx. 44% as metabolites) and via feces (approx. 15%). Terminal elimination half-life (T1/2) averages approximately 7.5 hours.

LuciOlap is indicated in adult patients for (in the presence of confirmed BRCA mutations or per clinical guidelines):

  • Ovarian Cancer: First-line maintenance treatment of patients with advanced epithelial ovarian cancer harboring BRCA mutations, as well as relapsed serous ovarian cancer.
  • Breast Cancer: Treatment of HER2-negative metastatic breast cancer with germline BRCA mutations.
  • Pancreatic Cancer: Maintenance treatment of metastatic pancreatic cancer with germline BRCA mutations.
  • Prostate Cancer: Treatment of metastatic castration-resistant prostate cancer with HRR gene mutations.

LuciOlap is administered orally twice daily every day (morning and evening) approximately every 12 hours.

Dosing Regimen:
The recommended standard dose is 300 mg (two 150 mg tablets) twice daily (total daily dose of 600 mg, corresponding to four 150 mg tablets per day).

Administration Guidelines:
Tablets should be swallowed whole with water; do not break, crush, chew, or divide. Can be taken with or without food. If a dose is missed or vomiting occurs after ingestion, take the next dose at the scheduled time (do not double doses).

Administration of LuciOlap is contraindicated in:

  • Hypersensitivity: Known hypersensitivity to olaparib or any excipient.
  • Pregnancy and Lactation: Strictly contraindicated in pregnant or breastfeeding women.
  • Pediatric Population: Safety and efficacy in patients under 18 years have not been established.
  • Severe Hepatic or Renal Impairment: Pronounced liver or kidney dysfunction.

Olaparib is metabolized primarily via CYP3A4:

  • Strong and Moderate CYP3A4 Inhibitors (ketoconazole, itraconazole, clarithromycin, ritonavir, grapefruit juice): May significantly elevate olaparib plasma concentrations and toxicity risks (avoid concurrent use or reduce dose).
  • Strong and Moderate CYP3A4 Inducers (rifampicin, carbamazepine, phenytoin, St. John's Wort): Significantly decrease olaparib blood concentrations and reduce efficacy (avoid concurrent use).
  • Vaccination: Administration of live vaccines is not recommended during olaparib treatment.

Pregnancy:
LuciOlap is contraindicated during pregnancy. Based on its mechanism of action, olaparib may cause fetal harm and embryotoxicity when administered to pregnant women. Females of reproductive potential must utilize effective reliable contraception during treatment and for at least 6 months following the final dose.

Lactation:
Excretion of olaparib into human breast milk is unstudied, though risk to the child cannot be ruled out. Breastfeeding must be discontinued during treatment and for 1 month post-therapy.

The most frequent and clinically significant adverse reactions include:

  • Gastrointestinal Tract: Nausea, vomiting, diarrhea, dyspepsia, abdominal pain, decreased appetite.
  • Hematologic Toxicity: Anemia, neutropenia, thrombocytopenia, leukopenia (routine complete blood count monitoring required).
  • General Disorders: Fatigue, asthenia, headache, dizziness, cough, dyspnea.
  • Rare but Serious Effects: Myelodysplastic syndrome (MDS) / acute myeloid leukemia (AML), pneumonitis.

Symptoms:
Specific acute overdose symptoms of olaparib are unestablished. Anticipated manifestations include exacerbated adverse reactions (gastrointestinal and hematologic abnormalities).

Treatment:
No specific antidote exists. In case of overdose, withhold treatment and initiate supportive and symptomatic care under medical supervision.

Storage Requirements for LuciOlap 150 mg:

  • 🌡️ Temperature Range: Store in original packaging in a dry place protected from light at temperatures below 30 °C.
  • 👶 Safety Precautions: Keep strictly out of reach of children (cytotoxic antineoplastic agent).
  • ⏳ Shelf Life: Stated on carton and blister pack. Don't use past expiration date. Prescription-only oncology medicine.

To verify authenticity of genuine LuciOlap 150 mg manufactured by Lucius Pharmaceuticals, inspect the following security and visual features:

  • ✅ Security Hologram & Scratch Code: Outer carton features an official Lucius Pharmaceuticals anti-counterfeit holographic seal with a scratch-off verification code for online validation via the manufacturer's official portal.
  • ✅ Corporate Branding: High-resolution printing displaying Lucius Pharmaceuticals graphics, Olaparib Film-coated Tablets 150 mg, and 120 Tablets count.
  • ✅ Factory Markings: Clearly printed Batch No., Mfg. Date, and Exp. Date matching across outer packaging and internal blister packs.
  • ✅ Prescribing Information: Includes an official product leaflet inside the outer carton.
On order · from 10 days
100% original product
Delivery across Ukraine
1

Notice. The information on this page is for reference only and does not replace medical consultation. Always consult a healthcare professional and read the manufacturer's instructions before using any medicine. Self-medication may be dangerous. Information updated: 15.11.2026

Customer reviews

No reviews yet

Your review can be the first!

Contact us

Choose a convenient way to contact

We work daily from 9:00 to 20:00